Trials / Completed
CompletedNCT00163137
Comparison of Raloxifene and Lasofoxifene - A Randomized, Blinded Study of These Drugs and Placebo on Bone Loss
Double-Blind Placebo-Controlled Trial Of The Safety, Toleration and Efficacy Of Lasofoxifene 0.25 Mg/D and Raloxifene 60Mg/D For The Prevention Of Bone Loss In Postmenopausal Women
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 540 (actual)
- Sponsor
- Ligand Pharmaceuticals · Industry
- Sex
- Female
- Age
- 48 Years – 75 Years
- Healthy volunteers
- Accepted
Summary
To compare the effects of 2 years of lasofoxifene treatment with 2 years of raloxifene 60 mg/day use and 2 years of placebo use on bone mineral density (BMD) of the lumbar spine.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | lasofoxifene | lasofoxifene 0.25mg |
| DRUG | raloxifene | raloxifene 60 mg/day |
| DRUG | Placebo | 0 mg/day |
Timeline
- Start date
- 2003-05-01
- Primary completion
- 2005-10-01
- Completion
- 2005-10-01
- First posted
- 2005-09-13
- Last updated
- 2011-08-12
Locations
72 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00163137. Inclusion in this directory is not an endorsement.